[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
June 2016

Hypertrophic Cardiomyopathy—One Case per Year?A Clarion Call to Do What Is Right

Author Affiliations
  • 1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
JAMA Cardiol. 2016;1(3):333-334. doi:10.1001/jamacardio.2016.0277

Hypertrophic cardiomyopathy (HCM) has fascinated (and scared) cardiologists for years owing, in part, to the relatively few cases most physicians will see in their practice, coupled with increased risk for sudden death, complex yet incomplete genetic understanding, and enigmatic hemodynamics. The management of symptomatic patients with HCM evolved over the past (nearly) 6 decades owing to focused efforts to understand the pathophysiology and perfect the necessary skills to delivery exemplary outcomes.1 We have learned that it is entirely possible for patients with HCM to have excellent quality of life and normal lifespans, that most patients can be treated with pharmacologic therapy, and that for most patients who remain symptomatic, there are procedures that can deliver excellent benefit with low risk.

×